Full Fed. Circ. Won't Rethink Pfizer's Paxlovid IP Win
The full Federal Circuit on Thursday won't disturb a panel's refusal to revive a patent that Enanta Pharmaceuticals had accused Pfizer of infringing through its blockbuster Paxlovid COVID-19 treatment....To view the full article, register now.
Already a subscriber? Click here to view full article